{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-013662","form_type":"8-K","ticker":"SER","cik":"0001708599","company_name":"Serina Therapeutics, Inc.","filed_at":"2023-04-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.148483+00:00","generated_at":"2026-06-16T13:10:45.833379+00:00","sec_items":["3.01","9.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"AgeX receives NYSE American delisting notice for low stockholders' equity; faces potential delisting by May 17, 2023","bullets":["NYSE American cited AgeX for stockholders' equity below $2M, $4M, and $6M thresholds with sustained losses.","AgeX must comply or show progress by May 17, 2023, or delisting proceedings will be initiated.","If delisted, AgeX plans to have its common stock quoted on an electronic interdealer quotation system (OTC).","AgeX remains subject to conditions from prior deficiency letters regarding stockholders' equity."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-013662","json":"https://secwatch.observer/filing/0001493152-23-013662.json","markdown":"https://secwatch.observer/filing/0001493152-23-013662.md","text":"https://secwatch.observer/filing/0001493152-23-013662.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1708599/000149315223013662/0001493152-23-013662-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1708599/000149315223013662/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-16T13:10:45.833379+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3ef3faa96177bbc7127a34bb8ca2fa25e9160e09","claim":"Serina Therapeutics, Inc. received a nyse_american deficiency notice notice regarding stockholders equity (rules 1003(a)(i), 1003(a)(ii), 1003(a)(iii)).","evidence_excerpt":"April 20, 2023, AgeX received a letter (the “Deficiency Letter”) from the staff of the NYSE American (the “Exchange”) indicating that AgeX does not meet certain of the Exchange’s continued listing standards as set forth in Sections 1003(a)(i), (ii), and (iii) of the Exchange Company Guide in that AgeX has stockholders equity of less than (A) $2,000,000 and has incurred losses from continuing operations and/or net losses during its two most recent fiscal years, (B) $4,000,000 and has incurred losses from continuing operations and/or net losses during three out of four of its most recent fiscal","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1708599/000149315223013662/0001493152-23-013662-index.htm","confidence":0.9,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nyse american"},{"label":"Notice","value":"deficiency notice"},{"label":"Deficiency","value":"stockholders equity"},{"label":"Rules","value":"1003(a)(i), 1003(a)(ii), 1003(a)(iii)"}],"fact_type":"exchange_compliance_notice"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}